Structure of broadly neutralizing antibody AR3B

An alternate conformation of HCV E2 neutralizing face as an additional vaccine target.

LLEQSGPEVKKPGSSVKVSCKDSGDTFNEPVTWVRQAPGQGLEWIGGIIPAFGVTKYAQKFQGRVIISADASTATAYLEL
SSLRSEDTAVYYCAKVGLRGIVMVGGLAMNWLDPWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCGS

EIELTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLE
PEDFAVYYCQQYGSSPQTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS
QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

20% (w/v) PEG 3350, 0.2M Na thiocyanate, 10% ethylene glycol

National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)

HCV, broadly neutralizing antibodies, bNAbs, E2 core, IGHV1-69, IMMUNE SYSTEM